Lung Protective Ventilation Strategies

Status Completed

Clinical Trial Summary

Obesity is becoming a common condition and bariatric metabolic surgery is one of the main options for treating morbid obesity. However, since most patients undergoing robotic bariatric surgery are class III obese, it brings new challenges to perioperative anesthesia management. Here, we explored the effects of lung-protective ventilation strategies on pulmonary oxygenation function and respiratory mechanics in patients undergoing robotic bariatric surgery.

Clinical Trial Description

Forty obese patients who underwent robotic bariatric surgery in our hospital were selected and randomly divided into a lung-protective ventilation strategy group (Group P) and a control group (Group C). The volume-controlled mode was used to assist ventilation, and the inspiratory/expiratory ratio (I: E) was 1:2. Tidal volume (VT) was set according to the Predicted body weight (PBW) throughout the whole procedure, and in group C, VT was 9 ml /kg without Positive end-expiratory pressure (PEEP), and the inhaled oxygen concentration (Fraction of oxygen) was 0.5 ml /kg, while the inspiratory oxygen concentration (Fraction of oxygen) was 0.5 ml /kg. Group C: VT 9ml /kg, no Positive end-expiratory pressure (PEEP), Fraction of inspiration O2 (FiO2) of 60%; Group P: the ventilation mode was the same as that of Group C from tracheal intubation to the beginning of pneumoperitoneum for 10 minutes, and after 10 minutes of pneumoperitoneum, the ventilation mode was the same as that of Group C. After the pneumoperitoneum for 10 minutes, the ventilation mode was VT 7ml/kg, PEEP 6cmH2O, FiO2 of 40%, and the plateau pressure was maintained at <30cmH2O. In both groups, the intraoperative gas flow was 2L/min, and SpO2 was maintained at ≥95%; if it could not be maintained, the oxygenation function of the patients could be improved by adjusting the ventilation parameters and strategies; meanwhile, the respiratory rate (RR) was adjusted to maintain the End-tidal carbon dioxide partial pressure (PETCO2) at ≥30%, and the end-tidal carbon dioxide partial pressure (PETCO2) was maintained at ≥30%, and the end-tidal carbon dioxide partial pressure (PETCO2) was maintained at ≥30%. The respiratory mechanical parameters: tidal volume, RR, airway peak pressure (PPeak), plateau pressure (PPeak), and plateau pressure (PPeak) were recorded at 5 minutes after tracheal intubation (T0), 10 minutes after the start of the pneumoperitoneum (T1), 60 minutes (T2), 120 minutes (T3), and 10 minutes after the pneumoperitoneum was closed (T4). pressure (PPeak), and plateau pressure (PPlate), and calculate the dynamic lung compliance; arterial blood was drawn at T0, T1, T2, T3, and T4, respectively, and the arterial partial pressure of oxygen (PaO2) and the arterial partial pressure of carbon dioxide (Arterial CO2) were measured. The arterial partial pressure of oxygen (PaO2) and arterial carbon dioxide pressure (PaCO2) were measured, and the oxygenation index (OI) was calculated. ;

Study Design

Related Conditions & MeSH terms

Respiration

Clinical Trial Details

NCT number	NCT06247943
Study type	Interventional
Source	Tianjin Medical University General Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2024
Completion date	March 17, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00730119` - Evaluation Of The GE Monitor Product Line	N/A
Not yet recruiting	`NCT05621642` - Telerehabilitation Based Exercise Training in Parkinson's Patients	N/A
Recruiting	`NCT06354400` - Core Stabilization Training on Chest Expansion, Functional Capacity, Trunk Muscle Endurance in Hearing-Impaired Children	N/A
Completed	`NCT01176539` - Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitor	N/A
Recruiting	`NCT05302219` - Plethysmography Curve Variability Depending on the Breath Cycle	N/A
Completed	`NCT03153345` - The Efficacy of Bedside Respiratory Muscle Training in Stroke Patients	N/A
Not yet recruiting	`NCT05886153` - Verification Protocol for the Cloud DX Vitaliti Continuous Vital Signs Monitor (VERDICT-2)	N/A
Recruiting	`NCT01324817` - Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitors for Use With Neonates	N/A
Completed	`NCT00827905` - Substantial Equivalence Study for Kai Sensors RSpot Non-Contact Respiratory Rate Spot Check	N/A
Completed	`NCT02946502` - Handgrip Strength Value in Predicting Mechanical Ventilation Weaning	N/A
Completed	`NCT01694979` - Pelvic Floor Activity and Breathing in Women	N/A
Withdrawn	`NCT01062789` - Optical Breath-hold Control System for Image-guided Procedures	Phase 0
Completed	`NCT00893087` - Comparison of Pressure-, Flow- and Neurally Adjusted Ventilatory Assistance (NAVA)-Triggering in Pediatric and Neonatal Ventilatory Care	N/A
Completed	`NCT00730054` - Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers	Phase 1/Phase 2
Completed	`NCT03119103` - Functional Bed Sheet Capturing Pressure Variation and Respiratory Effort Over Time	N/A
Recruiting	`NCT03206528` - Clinical Evaluation of the Vital Signs Monitoring System (VSMS)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.